MD Anderson Cancer Center
1515 Holcombe Boulevard
261 articles with MD Anderson Cancer Center
With an initial capital of $50 million, MD Anderson and partner The Focus Fund hope to invest in small biotechs with big cancer-fighting potential.
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials
Combination of over $50 million in committed capital along with access to cancer expertise and clinical facilities will help advance novel IND-ready candidates
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA
First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical collaboration with Nanobiotix
9/28/2020The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia
Astex Pharmaceuticals, Inc., and The University of Texas MD Anderson Cancer Center announces a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational treatments for pa
WAT Medical Enterprise has been supporting the world's cancer research. They donated part of the profits from selling EmeTerm on Amazon to the M.D. Anderson Cancer Center to support the development of global cancer. After making the donation in August 2019 , WAT Medical Enterprise will continue to support the cause of M.D. Anderso
Perimeter Medical Imaging Announces Expansion of ATLAS AI Project with Installation of OTISTM for AI development at Leading Cancer Care Center, MD Anderson
400 Patients Expected to be Enrolled in CPRIT-Backed Artificial Intelligence Development Study in Breast Cancer
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.
6/1/2020In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs
5/4/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic
NuProbe Announced New Clinical Advisory Board Members from Yale and MD Anderson, Launched NGS Multi-gene Panels
NuProbe, a molecular diagnostic startup, announced the addition of two world-renowned oncologists to their clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel, M.D., Ph.D., from Yale University School of Medicine.
Purchase price of $15 million from sale of manufacturing, office and laboratory facility
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
InxMed Co., Ltd. announced that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
Expects Delivery and Sales of Initial RAP Devices for Tattoo Removal in Mid-2020